PDF Cover

Closed Drug Transfer Systems Market

The market for Closed Drug Transfer Systems was estimated at $1.7 billion in 2024; it is anticipated to increase to $2.8 billion by 2030, with projections indicating growth to around $4.4 billion by 2035.

Report ID:DS1801331
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Closed Drug Transfer Systems
Share
Report Price: $4,200
Report Summary
Market Data
Methodology
Table of Contents

Global Closed Drug Transfer Systems Market Outlook

Revenue, 2024

$1.7B

Forecast, 2034

$4.0B

CAGR, 2025 - 2034

9.1%

The Closed Drug Transfer Systems (CDTS) industry revenue is expected to be around $1.8 billion in 2025 and expected to showcase growth with 9.1% CAGR between 2025 and 2034. The strong expansion of the Closed Drug Transfer Systems market is mainly fueled by the rising demand for safety precautions in healthcare settings with a focus on oncology therapies. The growing occurrence of exposure to drugs and the risks it carries have made it essential to implement these systems which highlights their continued importance. Moreover advancements, in technology and strict regulatory standards are also factors influencing the market trends of Closed Drug Transfer Systems.

In healthcare settings like hospitals and clinics well as pharmaceutical industries have introduced Closed Drug Transfer Systems to ensure safety for medical workers, against hazardous drugs when they are being handled during preparation and disposal procedures.

Closed Drug Transfer Systems market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Closed Drug Transfer Systems Market Outlook

Market Key Insights

  • The Closed Drug Transfer Systems market is projected to grow from $1.7 billion in 2024 to $4.0 billion in 2034. This represents a CAGR of 9.1%, reflecting rising demand across Oncology Treatment, Pharmaceutical Manufacturing, and Veterinary Medicine.

  • Becton Dickinson and Company, Equashield LLC, ICU Medical Inc. are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Closed Drug Transfer Systems market and are expected to observe the growth CAGR of 6.6% to 9.6% between 2024 and 2030.

  • Emerging markets including Brazil, South Africa and Indonesia are expected to observe highest growth with CAGR ranging between 8.7% to 11.4%.

  • Transition like Technological Advancements is expected to add $109 million to the Closed Drug Transfer Systems market growth by 2030.

  • The Closed Drug Transfer Systems market is set to add $2.3 billion between 2024 and 2034, with manufacturer targeting Ambulatory Surgical Centers & Specialty Clinics Application projected to gain a larger market share.

  • With

    increasing prevalence of occupational hazards, and

    Technological Advancements in Drug Delivery Systems, Closed Drug Transfer Systems market to expand 139% between 2024 and 2034.

closed drug transfer systems market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Closed Drug Transfer Systems - Country Share Analysis

Opportunities in the Closed Drug Transfer Systems

Building partnerships and working together with healthcare facilities and pharmaceutical companies can also give CDTS an advantage, in the market landscape by tailoring solutions to meet specific needs effectively.

Growth Opportunities in North America and Asia Pacific

North America holds a position in the Closed Drug Transfer Systems market with the United States being a key player in this field. The regions advanced healthcare infrastructure and strict safety regulations in the pharmaceutical industry contribute to its presence. Leading manufacturers and a high prevalence of illnesses further boost the demand for Closed Drug Transfer Systems here. Despite this position the market encounters tough competition, from local and global competitors calls for ongoing innovation and strategic collaborations to stay competitive.
The Asia Pacific region is becoming a market for Closed Drug Transfer Systems with China and India at the forefront of this growth trend. A rising understanding of the need for safe drug transfer combined with increased healthcare spending in these nations is driving market expansion. Manufacturers are seeing prospects in the region due to the growing demand for state of the art systems and the uptick, in diseases that call for intricate drug administration methods. The competition is getting tougher as new players join the fray. Technological advancements and government efforts to ensure healthcare safety are factors driving the market forward.

Market Dynamics and Supply Chain

01

Driver: Increasing Prevalence of Occupational Hazards, and Strict Regulatory Guidelines for Drug Handling

The rising occurrence of workplace risks in healthcare environments plays a role in the expansion of the Closed Drug Transfer Systems market sector. These systems are also tailor made to shield healthcare professionals from drug exposure thereby safeguard their well being. The utilization of Closed Drug Transfer Systems is also projected to experience advancement owing to the growing emphasis on ensuring occupational safety, within healthcare facilities.

The stringent regulatory guidelines for the handling and administration of hazardous drugs are also another significant market. The need for compliance with these guidelines is also leading to increased adoption of Closed Drug Transfer Systems, especially in developed countries. The systems used for handling cytotoxic and antiviral drugs are also expected to benefit the most from this .

The market for CDTS is also also experiencing growth due to improvements in drug delivery technology advancements that aim to create systems that are also more efficient and user friendly while ensuring safety standards are also met and exceeded in the market landscapes growth trajectory is also expected to be uplifted by these developments with a focus, on applying these innovative systems primarily in chemotherapy and other high risk drug administration scenarios anticipated to witness substantial growth trends.

02

Restraint: High Costs of Installation

Closed Drug Transfer Systems often entail financial commitment as they involve high expenses for acquiring the system and providing training to healthcare staff members. The associated costs can pose a challenge, for numerous healthcare facilities operating on constrained budgets. These elevated installation expenses may hinder the acceptance of Closed Drug Transfer Systems and consequently restrict market expansion.

03

Opportunity: Expansion in Emerging Markets and Technological Advancements

In developing markets like India, China and Brazil the use of Closed Drug Transfer Systems is experiencing growth. These nations are seeing a rise in the enhancement of healthcare infrastructure and a heightened emphasis on ensuring safety. Implementating Closed Drug Transfer Systems in these areas can notably lower the chances of being exposed to medications creating a higher demand, for such systems.

The ongoing progress of technology in the healthcare industry offers potential for Closed Drug Transfer Systems . Advancements like linking with platforms for live monitoring and automated mechanisms, for accurate drug transfer have the capacity to improve the effectiveness and security of these systems.

04

Challenge: Lack of Awareness and Training

Despite the known benefits of CDTS, there is a lack of awareness and understanding about these systems among healthcare professionals. This lack of knowledge can lead to improper usage or even avoidance of these systems. Additionally, there is often a lack of adequate training provided to healthcare staff on the correct usage of these systems. This further compounds the issue, resulting in reduced market demand for CDTS.

Supply Chain Landscape

1

Raw Material Procurement

BASF SEDow Chemical Company
2

Component Manufacturing

Becton DickinsonICU Medical
3

Assembly & Testing

EquashieldYukon Medical
4

Distribution & End-User

Cardinal HealthBaxter International
Closed Drug Transfer Systems - Supply Chain

Use Cases of Closed Drug Transfer Systems in Oncology Treatment & Veterinary Medicine

Oncology Treatment : Closed Drug Transfer Systems are predominantly used in oncology departments to ensure the safe handling of cytotoxic drugs. These systems, such as the PhaSeal system from BD Medical, are designed to prevent the escape of hazardous drug vapors into the environment, thereby protecting healthcare workers from exposure. The unique advantage of using CDTS in oncology is the high level of safety and precision they offer in drug administration, reducing the risk of contamination. BD Medical is a key player in this application, known for its market-leading PhaSeal system.
Pharmaceutical Manufacturing : In the realm of pharmaceutical manufacturing, CDTS play a crucial role in maintaining the integrity of the manufacturing process. Systems like the Tevadaptor from Teva Pharmaceuticals are commonly used to transfer drugs from one stage of the process to another without exposure to the external environment. The key advantage of these systems in this application is their ability to maintain a sterile environment, crucial for the production of high-quality pharmaceuticals. Teva Pharmaceuticals is a leading player in this application, recognized for its innovative Tevadaptor system.
Veterinary Medicine : CDTS are increasingly used in veterinary medicine to ensure the safe administration of medications to animals while minimizing exposure to hazardous drugs. Systems like ChemoClave from ICU Medical, PhaSeal from BD, and Equashield from Equashield Inc. are commonly employed in veterinary clinics and hospitals. These systems protect veterinary staff from harmful drug exposure and ensure accurate, contamination-free drug delivery for animal patients.

Recent Developments

Closed Drug Transfer Systems have emerged as a critical component in the healthcare sector, particularly in oncology departments and other areas where hazardous drugs are frequently handled. The recent market developments have been largely driven by the increasing need for safety and efficiency in drug administration procedures.

December 2024 : PhaSeal Corporation launched a new closed drug transfer system, enhancing safety measures in the pharmaceutical sector
October 2024 : Becton Dickinson and Company introduced an advanced closed drug transfer system, improving efficiency in drug administration
August 2024 : Equashield LLC expanded its product portfolio with a novel closed drug transfer system, offering superior protection in handling hazardous drugs.

Impact of Industry Transitions on the Closed Drug Transfer Systems Market

As a core segment of the Medical Device industry, the Closed Drug Transfer Systems market develops in line with broader industry shifts. Over recent years, transitions such as Technological Advancements and Regulatory Compliance have redefined priorities across the Medical Device sector, influencing how the Closed Drug Transfer Systems market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Technological Advancements

The realm of CDTS has seen technological progress in recent years that has transformed how healthcare providers manage dangerous medications and improved safety for patients and medical staff alike. An example of this progress is the introduction of CSTDs equipped with safety features that minimize the chances of unintended exposure, to hazardous drugs. Ultimately boosting patient safety and healthcare effectiveness. This shift has not only influenced patient care but also spurred advancements in the pharmaceutical sector by promoting the creation of more refined and secure drug delivery methods.

02

Regulatory Compliance

The increasing emphasis on regulatory compliance is another major transition in the CDTS industry. Governments and healthcare organizations worldwide are implementing stricter regulations to ensure the safe handling of hazardous drugs. These regulations mandate the use of CSTDs in healthcare facilities, driving the demand for high-quality and compliant systems. This transition has led to a surge in the adoption of CSTDs in hospitals and pharmacies, promoting safer drug handling practices and reducing the risk of drug-related accidents.